• Shionogi will present exploratory Phase 3 analyses of COVID-19 drug Xocova (ensitrelvir) at IDWeek 2026.
• SCORPIO-PEP analyses found numerically lower viral levels and less severe symptoms among recipients with breakthrough infections or infection at enrollment versus placebo.
• A pooled analysis of two Phase 3 trials showed greater reductions in infectious virus versus placebo across age, vaccination and risk groups.
• The FDA authorized Xocova in May 2026 to prevent COVID-19 following exposure in adults and adolescents aged 12 and older.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210800BIZWIRE_USPR_____20261021_BW046869) on October 21, 2026, and is solely responsible for the information contained therein.